Seventure Partners

🙌 Today, Thursday 27 June, is the International Microbiome Day! An opportunity to highlight the particularly intense development of research into the human #microbiome in 2023, and the major milestones that have been reached in terms of #therapeutic targeting.   To find out more about current developments, download our report: 👉 ow.ly/5tMq50Ryf4M Isabelle de Cremoux #Microbiome #HealthforLifeCapital #Biotech #Research

Thank you to #InVivo (Norstella) for printing the article of Isabelle de Cremoux, our CEO, on the state of the #Biopharma market – not just from the POV of the companies, but also from the VCs that invest in them.   In summary, Biopharma markets may follow the downward trajectory of tech during tough times, but they also chase it back up the value curve. Recovery is just a matter of time, however, in those tough times, that’s when innovation and resourcefulness can deliver valuable long-term benefits.   #Microbiome #HealthforLifeCapital #Biotech #Pharma #PrivateEquity #Investment   To read the full article, follow the link https://lnkd.in/eiBX75n3  

🚀 Exciting News! We’re delighted to be part of Tubulis GmbH €128 Million Series B2 Funding Round which Seventure’s funds are supporting since 2020 🚀 Isabelle de Cremoux

"Microbiome Progress: A look at 2023" – our new report unveiled.   🙌 We are excited to announce publication of our new comprehensive report describing research advances in the human #microbiome in 2023. The author of the report, Isabelle de Cremoux, CEO and Managing Partner of Seventure Partners, assesses recent discoveries and developments and delves into the pivotal implications of these on health, clinical study progress, therapeutic, diagnostic, and nutritional products, and the food of tomorrow.   To obtain a free copy of the report, please send your request throught this link 👉 https://lnkd.in/eTmGm4JS   The report covers key themes:   ✅ Understanding the Gut Microbiome: Exploring its composition and intricate link to human health.   ✅ Therapeutic Breakthroughs: Targeting the microbiome to treat autoimmune, inflammatory, metabolic, and neurological disorders, with promising results already in cancer, autism, Parkinson's, and obesity.   ✅ Tech-Driven Developments: Embracing data standardization and leveraging machine learning and AI to expedite data processing and research.   ✅ Microbiome Products: State of play of first- and next-generation microbiome products, including fecal microbiome transplantation, Live Biotherapeutics, and more traditional drugs.   ✅ Expanding Horizons: Venturing beyond the gut microbiome to target other human microbiomes, such as the oral cavity, skin, vagina, and lungs.   *Beyond Medicine: Exploration of non-medicinal products – #prebiotics, #probiotics, #postbiotics, and #symbiotics.   #BIOTECH #NUTRITION #DEEPTECH #FOODTECH #HEALTHFORLIFECAPITAL

"Microbiome Progress: A look at 2023" – our new report unveiled.   🙌 We are excited to announce publication of our new comprehensive report describing research advances in the human #microbiome in 2023. The author of the report, Isabelle de Cremoux, CEO and Managing Partner of Seventure Partners, assesses recent discoveries and developments and delves into the pivotal implications of these on health, clinical study progress, therapeutic, diagnostic, and nutritional products, and the food of tomorrow.   To obtain a free copy of the report, please send your request throught this link 👉 https://lnkd.in/eTmGm4JS   The report covers key themes:   ✅ Understanding the Gut Microbiome: Exploring its composition and intricate link to human health.   ✅ Therapeutic Breakthroughs: Targeting the microbiome to treat autoimmune, inflammatory, metabolic, and neurological disorders, with promising results already in cancer, autism, Parkinson's, and obesity.   ✅ Tech-Driven Developments: Embracing data standardization and leveraging machine learning and AI to expedite data processing and research.   ✅ Microbiome Products: State of play of first- and next-generation microbiome products, including fecal microbiome transplantation, Live Biotherapeutics, and more traditional drugs.   ✅ Expanding Horizons: Venturing beyond the gut microbiome to target other human microbiomes, such as the oral cavity, skin, vagina, and lungs.   *Beyond Medicine: Exploration of non-medicinal products – #prebiotics, #probiotics, #postbiotics, and #symbiotics.   #BIOTECH #NUTRITION #DEEPTECH #FOODTECH #HEALTHFORLIFECAPITAL

Soil Microbotia: 👏 to Starfish bioscience, a trailblazer in microbiological solutions for agriculture and viticulture which has successfully raised € 900,000 in seed only 2️⃣ mouths after the company was founded! ➡️This investment is a strategic move towards addressing the challenges of sustainable agriculture and acknowledges the rising interest in the microbiomes of food systems. ➡️It aligns with the global shift towards sustainable practices in agriculture, food production, and overall ecosystem health. #DeeptechGreen #Biotech #Agtech #Winetech #Microbiome

"For many years, at Seventure Partners, through our Health For Life Captal™ I & II funds, we have been investing in technologies and research sectors that respond to major societal and environmental challenges. The microbiome, our field of excellence for over 10 years, is now the focus of attention in all sectors involving agriculture, nutrition and health. I'm delighted to see that the World Economic Forum has taken up this topic. Respecting the microbiome of soils and crops means better protecting human health. We are very close to the biotech companies that are enhancing the value of micro-organisms for more responsible agriculture, and we invite you to keep an eye on our forthcoming announcement", comments our CEO Isabelle de Cremoux. World Economic Forum #Microbiome #AgTech #FoodScience #Investments https://lnkd.in/eXmHNewR

Retrouvez la tribune de notre CEO Isabelle de Cremoux publiée ce jour dans Les Echos sur un des secteurs économiques des plus dynamique : Le SPORT ! "Pour un investisseur, le secteur du sport représente donc un terrain de jeu prometteur pour la diversification de son portefeuille. L'univers d'investissement est non seulement immense, mais il est également en expansion continue : chaque année, ce sont ainsi plus de 300 sociétés non cotées européennes qui lèvent des fonds afin de financer leur croissance." Lire l'intégralité 👉 https://lnkd.in/gacvqwNd 🚀 Bpifrance : Joignons nos forces pour continuer à propulser la #sportech française à l'aube des #JO #Paris2024 ! 🏅

📢 Exciting News! Enterome Joins LLS TAP to Accelerate Breakthrough Blood Cancer Therapeutics 🚀 Enterome has been selected to be a part of The Leukemia & Lymphoma Society's Therapy Acceleration Program® (LLS TAP) – a groundbreaking initiative aimed at fast-tracking innovative treatments for blood cancers. 🩸 With a strategic equity investment of €3 million, LLS TAP is joining forces with Enterome to drive the clinical advancement of EO2463 in Non-Hodgkin's Lymphoma. This substantial investment is a significant step towards transforming the landscape of blood cancer therapeutics and bringing hope to patients worldwide. 💪 Fulle press release 👉 https://lnkd.in/epTkxZkM #Microbiome #Cancer #Research #Leukemia Belichard Pierre Isabelle de Cremoux The Leukemia & Lymphoma Society

[Health for Life Capital™ Portfolio] We're thrilled to announce a game-changing merger that's set to redefine microbiome research: Clinical Microbiomics and CosmosID are uniting to create the Global Leader in Microbiome Research Services! This merger happens a year after a 10 million investment from Seventure, who is the only investor in Clinical Micronomics with its health and nutrition microbiome focused Health for Life Capital™ II fund. It will allow to create the first-ever microbiome service company with a global infrastructure, aiming to uncover the microbiome's impact on health and well-being across all life domains. Read the full press release 👉 https://lnkd.in/dJj57dXG   Isabelle de Cremoux Anders Grøn Manoj Dadlani #MicrobiomeInnovation #MicrobiomeResearch #biotech #nutrition #foodtech #agtech #privateequity